Huma Therapeutics announced the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharma and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.
A further commitment of $70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200 million. Goldman Sachs International acted as lead placement agent to Huma. HSBC Bank plc± and Nomura acted as joint placement agents, with the latter also becoming a shareholder.
“The new investment will be used to expand Huma’s digital platform in the US, Asia and the Middle East. Its digital ‘hospital at home’ was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90 per cent. The service is supporting governments’ pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery e.g. with Smith+Nephew,” informed the company through a statement.
Huma works with several life science companies including AstraZeneca, Bayer and Janssen and academic institutions such as Stanford Medicine, the Johns Hopkins Bloomberg School of Public Health and the University of Cambridge.